17 nov: Aktier/åbning: Lundbeck og Rockwool i fokus i rødt marked
17 nov: Rockwool leverede lavere omsætning men bedre resultat end ventet
17-11-2016 09:26:42

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
29 nov - 
Zealand Pharma/SHB: Sænker anbefaling til "reducer" fra..
25 nov - 
Zealand Pharma udvider kapital efter udnyttelse af warr..
22 nov - 
Genmab får løftet kursmålet efter vigtig godkendelse i ..
Relateret debat
00:34 - 
Vrøvl
00:34 - 
Er også i ZP men dit bud er ude i hampen i min verden.
00:16 - 
Forstår ikke din logik Baron, jo det er hurtige penge, ..

Company announcement - No. 45 / 2016

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 17 November 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 8,200 divided into 8,200 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs.

Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 per share and the total proceeds to Zealand from the capital increase amounts to DKK 631,400.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,070,453 divided into 26,070,453 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as AdlyxinTM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus® (insulin glargine) which product is under regulatory review in the United States and in Europe. 

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide* (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN)

45-16_1117 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 771002.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13 jan
ZEAL
Goodwrench, jeg har i lang tid ignoreret dine destruktive indlæg og havde håbet på, at alle øvrige s..
43
17 jan
ZEAL
http://mediaroom.sanofi.com/suliquatm-approved-in-the-european-union-for-the-treatment-of-adults-wit..
12
13 jan
ZEAL
Grøn strømpil til Zealand Pharma (opdateret liste)   - Godkendelsen af Suliqua(TM) på plads   - Suli..
9
16 jan
ZEAL
Måske har bestyrelsesformanden i Nordea ret med hensyn til 80 % segmentet i banken. Men Nordea Liv o..
8
16 jan
ZEAL
Læs selv
6
13 jan
ZEAL
Mon ikke vi får svar fra EMA i denne weekend eller næste weekend - og gerne en godkendelse :-)   Her..
6
17 jan
ZEAL
Eller 116 eller 109 Man kan ikke bruge TA til en disse
3
17 jan
ZEAL
Nej, man kan ikke regne sig frem til hvor mange recepter som er udskrevet på Soliqua. Men som med Pa..
3
16 jan
ZEAL
Der er ikke noget nyt i artiklen. Thorleif Jackson har kikket på salgsestimaterne og regnet sig frem..
3
13 jan
ZEAL
Er det virkelig voksne mennesker herinde ? Det er blå stue om igen
3

Norden/Carnegie: Sænker anbefaling til "sælg" fra "hold"

17-01-2017 15:20:25
Finanshuset Carnegie sænker anbefalingen af aktien i rederiet Norden til "sælg" fra "hold". Kursmålet er uændret 95 kr.Det fremgår af data fra Bloomberg News.No..

Shipping: Baltic Dry-indekset falder 0,3 pct. til 922 point

17-01-2017 14:05:16
Tørlastindekset Baltic Dry falder tirsdag med 0,3 pct. til 922 point. Det fremgår af data fra Bloomberg News.Baltic Dry-indekset udarbejdes af London-baserede B..

Aktier/åbning: Goldman giver Genmab gylden håndsrækning

17-01-2017 09:23:35
Et løftet kursmål fra den amerikanske investeringsbank Goldman Sachs har tirsdag sendt Genmab på vinderkurs i det toneangivende C20 Cap-indeks.Der er dog tale o..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo og Genmab får løftet kursmål - ris til FLS og ALK
2
Aktier/åbning: Goldman giver Genmab gylden håndsrækning
3
Godt nyt til boligejerne: Uventet dyk i korte renter
4
Britisk leder melder om totalt exit fra EU og indre marked - NY2
5
General Motors efter kritik fra Trump: Investerer 1 mia. dollar i USA

Relaterede aktiekurser

Zealand Pharma A/S 121,00 6,6% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. januar 2017 02:35:30
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170103.1 - EUROWEB5 - 2017-01-18 02:35:30 - 2017-01-18 02:35:30 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x